PRODUCT DESCRIPTION:

Vecuronium Bromide Injection is a non-depolarizing skeletal muscle relaxant widely used during surgical and critical care procedures to facilitate endotracheal intubation and ensure muscle relaxation.

It functions by competitively inhibiting acetylcholine at neuromuscular junctions without causing fasciculations, offering a smooth onset and intermediate duration of action.

It is ideal for use during general anesthesia or in intensive care settings where mechanical ventilation is required. Manufactured under stringent cGMP norms, the product is sterile, pyrogen-free, and stable, ensuring global compliance for institutional and hospital sourcing.

Formulation & Presentation:

• Dosage Form: Sterile Injectable
• Presentation: Clear Sterile Solution in Clear/Amber Glass Vial/ Ampoule (customizable as per market demand)
• Available Strengths:
  • Vecuronium Bromide Injection: 4 MG
  • Vecuronium Bromide Injection: 10 MG
  • Vecuronium Bromide Injection: 20 MG
• Route of Administration: Via Intravenous (IV) Bolus or Intramuscular (IM) routes or as advised by physician. To be used after appropriate reconstitution or as per clinical indication and recommendation. Reconstituted as per protocol for injection in country of use. To be administered under strict supervision of a qualified doctor or as per physician’s discretion or decision only.

Therapeutic Indications:

• Induction of general anesthesia
• Short surgical or diagnostic procedures
• Control of convulsions in status epilepticus
• Sedation in neurocritical care units
• Rapid sequence intubation (RSI) in emergency settings

Side Effects:

• COMMON:
  • Prolonged muscle weakness
  • Hypotension
  • Mild injection site discomfort
  • Bradycardia
• SERIOUS (RARE):
  • Respiratory depression or apnea
  • Anaphylactic reactions
  • Prolonged neuromuscular blockade
  • Cardiac arrhythmias
• PRECAUTIONS:
  • Administer only by trained professionals in controlled settings
  • Ensure continuous monitoring of respiratory and cardiovascular function
  • Dosage adjustment may be required in patients with hepatic or renal impairment
  • Should be used with caution in patients with neuromuscular diseases (e.g., myasthenia gravis)
  • Reversal agents (e.g., neostigmine) should be readily available